XML 77 R55.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies - Other Agreements (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jan. 31, 2018
Aug. 31, 2017
Dec. 31, 2016
Oct. 31, 2014
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Mar. 31, 2017
Dec. 16, 2016
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Research and development         $ 157,996 $ 96,898 $ 90,654      
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | License Patent Rights                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Upfront fee       $ 200            
Stock issued to licensors       561,531            
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 License Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Research and development     $ 16,500              
Common stock issued for settlement 150,606 271,347           479,270    
Market capitalization         $ 2,500,000          
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 License Agreement | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Royalties credit paid to third party (as a percent)         50.00%          
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 License Agreement | Accrued expense                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Success payment accrued         $ 15,000          
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 Success Payments | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Success payments         10,000,000          
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 Success Payments | Minimum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Success payments         750,000          
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 Market Cap Success Payments                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Market capitalization               $ 1,000,000 $ 750,000  
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 Market Cap Success Payments | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Success payments         125,000          
Market capitalization threshold         10,000,000          
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cas9-II License Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Common stock issued for settlement 75,303                  
Market capitalization               $ 1,000,000    
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cas9-II License Agreement | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Success payments         30,000          
Market capitalization threshold         9,000,000          
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cas9-II License Agreement | Minimum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Market capitalization threshold         1,000,000          
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Rare disease | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential liability for future sales milestone payments       $ 36,000            
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Rare disease | Cpf1 License Agreement | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential liability for future sales milestone payments         36,000          
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | License Patent Rights | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential liability for future clinical and regulatory milestone payments related to product approval       14,800            
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | Human disease | Cpf1 License Agreement | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential liability for future clinical and regulatory milestone payments related to product approval         20,000          
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | Human disease | Cas9-II License Agreement | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential liability for future clinical and regulatory milestone payments related to product approval                   $ 3,700
Potential liability for future sales milestone payments         13,500          
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | Rare disease | Cpf1 License Agreement | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential liability for future clinical and regulatory milestone payments related to product approval         6,000          
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | Rare disease | Cas9-II License Agreement | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential liability for future clinical and regulatory milestone payments related to product approval         1,100          
Potential liability for future sales milestone payments         9,000          
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States and one other | Human disease | License Patent Rights | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential liability for future clinical and regulatory milestone payments related to product approval       4,100            
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | UNITED STATES | Human disease | License Patent Rights | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential liability for future sales milestone payments       $ 54,000            
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | UNITED STATES | Human disease | Cpf1 License Agreement | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential liability for future sales milestone payments         $ 54,000